백혈병 치료 시장 : 시장 규모, 점유율, 동향 및 성장 분석(2026-2034년)

The global leukaemia therapy market size is expected to reach USD 44.00 Billion in 2034 from USD 24.44 Billion in 2025, growing at a CAGR of 6.75 during 2026-2034.This market is experiencing strong growth due to the increasing prevalence of blood cancers and rising advancements in oncology treatment technologies. Leukaemia therapies include chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation solutions designed to improve survival rates and patient outcomes. Growing awareness regarding early cancer diagnosis and increasing healthcare investments are significantly contributing to market expansion. Pharmaceutical companies and healthcare institutions are also investing heavily in innovative cancer treatment research to address the rising global burden of leukaemia cases.

The growing adoption of precision medicine, immunotherapy, and targeted treatment approaches is a major factor driving market growth. Advances in genetic testing and molecular diagnostics are enabling healthcare providers to develop personalized treatment plans for leukaemia patients. Government funding for cancer research programs and expanding clinical trial activities are also supporting innovation in oncology therapeutics. In addition, increasing collaboration between biotechnology firms and pharmaceutical companies is accelerating the development of advanced treatment solutions for different forms of leukaemia worldwide.

Future prospects for the leukaemia therapy market remain highly promising due to continuous advancements in cancer research and immunotherapy technologies. Companies are expected to focus on cell-based therapies, gene editing technologies, and next-generation targeted drugs to improve treatment effectiveness and reduce side effects. The integration of artificial intelligence in oncology diagnostics and drug discovery is likely to create additional growth opportunities. Emerging economies are also anticipated to witness increased adoption as healthcare infrastructure strengthens and cancer awareness programs expand globally.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Treatment Type

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• CAR-T Cell Therapy
• Gene Therapy
• Stem Cell Transplantation
• Other Treatment Types

By Leukemia Type

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Other Leukemia Types

By Therapy Modality

• Small-Molecule Drugs
• Monoclonal Antibodies
• CAR-T Cell Therapies
• Gene Therapies
• Bispecific Antibodies
• RNA-based Therapies
• Other Modalities

By Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Other Routes

By Age Group

• Pediatric (<14 yrs)
• Adult (15-64 yrs)
• Geriatric (65+ yrs)

COMPANIES PROFILED

• Novartis International AG, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson, Pfizer Inc., AstraZeneca plc, AbbVie Inc., Amgen Inc., Gilead Sciences Inc., Takeda Pharmaceutical Company Limited, Sanofi S.A., Bayer AG, Astellas Pharma Inc., BeiGene Ltd., Incyte Corporation

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LEUKAEMIA THERAPY MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment Type
• 4.2. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. CAR-T Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Stem Cell Transplantation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Other Treatment Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LEUKAEMIA THERAPY MARKET: BY LEUKEMIA TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Leukemia Type
• 5.2. Acute Lymphoblastic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Acute Myeloid Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Chronic Lymphocytic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Chronic Myeloid Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Leukemia Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LEUKAEMIA THERAPY MARKET: BY THERAPY MODALITY 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Therapy Modality
• 6.2. Small-Molecule Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. CAR-T Cell Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Gene Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Bispecific Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. RNA-based Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Other Modalities Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LEUKAEMIA THERAPY MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Other Routes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL LEUKAEMIA THERAPY MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Age Group
• 8.2. Pediatric (<14 yrs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Adult (15-64 yrs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Geriatric (65+ yrs) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL LEUKAEMIA THERAPY MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Treatment Type
  • 9.2.2 By Leukemia Type
  • 9.2.3 By Therapy Modality
  • 9.2.4 By Route Of Administration
  • 9.2.5 By Age Group
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Treatment Type
  • 9.3.2 By Leukemia Type
  • 9.3.3 By Therapy Modality
  • 9.3.4 By Route Of Administration
  • 9.3.5 By Age Group
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Treatment Type
  • 9.4.2 By Leukemia Type
  • 9.4.3 By Therapy Modality
  • 9.4.4 By Route Of Administration
  • 9.4.5 By Age Group
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Treatment Type
  • 9.5.2 By Leukemia Type
  • 9.5.3 By Therapy Modality
  • 9.5.4 By Route Of Administration
  • 9.5.5 By Age Group
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Treatment Type
  • 9.6.2 By Leukemia Type
  • 9.6.3 By Therapy Modality
  • 9.6.4 By Route Of Administration
  • 9.6.5 By Age Group
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL LEUKAEMIA THERAPY INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Novartis International AG
  • 11.2.2 F. Hoffmann-La Roche Ltd
  • 11.2.3 Bristol-Myers Squibb Company
  • 11.2.4 Johnson & Johnson
  • 11.2.5 Pfizer Inc
  • 11.2.6 AstraZeneca Plc
  • 11.2.7 AbbVie Inc
  • 11.2.8 Amgen Inc
  • 11.2.9 Gilead Sciences Inc
  • 11.2.10 Takeda Pharmaceutical Company Limited
  • 11.2.11 Sanofi S.A
  • 11.2.12 Bayer AG
  • 11.2.13 Astellas Pharma Inc
  • 11.2.14 BeiGene Ltd
  • 11.2.15 Incyte Corporation